PYX Resources: Achieving volume and diversification milestones. Watch the video here.
I mean...it's AIM. It's not the FTSE or Premium Bonds. Its not safe. You come into it expecting to be bitten for bigger rewards down the line, or trading opposed if you trade. It's a gamble.
If you didn't understand that fledgling companies were not your buddy in arms why did people come here? You can't have blue days every day and shy-te happens here just as much as good times. How can people not know this? I've been on AIM 15 years and have seen it all, including what's happening here.
This has been done to death on AIM. All the risers have done this to the great chagrin of some holders. Then it was up, up and away and all forgotten as people doubled, tripled or multiplied their rewards. Because of something good the company later that was beneficial to holders. Its's business and not personal, though it feels bad at the time.
Ride or die, as it were. AIM isn't going to change for any of us, ever.
Scott, I'm in an ex-AIM company that the CEO has kept off market for almost SIX years, whilst he's fiddled, and drawn a salary from it, and we've been through hell.
Whatever you've been through here at varying degrees of pain, which i totally empathise with, take comfort from the fact you have an active, now well-funded company in HE1, sat snack bang on a globally-significant reserve with readings that are off all charts. And that you have a strong chance of getting something to all of your losses back in time. Maybe sooner than you think.
I now consider myself an investor, a shareholder here, and this doesn't bother me one bit. In fact it bodes well for the company's growth and our stability and prospects longer term.
You need ready money to advance, JV and further explore. As a shareholder I'm in for the longer term gains, not today or tomorrow.
...for next phase of growth. Oukd this be so strange for such a company? Could they go forward with little left in the coffers?
It's done and out-of the way so it can move forward. Just one of those things we have to roll with on AIM. Short term pain for longer term gain. And a good buying op if it goes down. GLA.
Apparently abundant so I'm told from Tele, but it still has numerous uses, including in 3D printing and the welding and car industry. And a direct feed at source would mean less refining. Maybe only a minor bonus but with these different gases the possibilities increase.
https://techiescientist.com/uses-of-argon/
To be honest I think it's being held back far more because someone wants someones mate/s onboard cheaply. When someones finished loading up they'll magically take their boot off the sps head. It's a common pattern on AIM. Hence why you get tonnes of trolling and doubting thomas' flooding in with their gaslit lamps, nitpicking every word. Even though they know they are wasting everyones time they're being paid for it. They load up on the very shares they carp at.
They just don't tell you that. ;)
Agreed. All that really matters now is impending RNSs/comms from company shoring up what they have and how they will go about tackling it. There will be characteristic wild pro and con noise on the bbs until that happens. It happened during GGP's big run, REM, XEL, RKH, Tullow, all the big risers. Just days and weeks of bunfights amounting to nothing but expended energy really, people blowing off steam. You're better off just switching off. The company has this one in the bag and that's that. Enjoy popping into the bbs but don't let it become your life or an addiction. We all know how silly these boards can get.
I'll report back if the newspapers decide to print up any Helium One stories after e-mailing a few links out today. Let's see what they come back with. GL holders.
'His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities.'
Looks to be gearing up for next stage objectives.
Biography
Vitalii holds a Master of Business Administration from the Kyiv University of Technology and Design, where he majored in Computer Science and minored in Behavioural Psychology. Vitalii has nine years of experience in the technology sector, beginning his career as a Data Engineer and Solution Architect for several Israeli companies. He has also been a foundational engineer in various start-ups, bringing his unique perspective and technical skills to the forefront of innovation. Vitalii currently works at an investment fund, where he creates quantitative models and tools to support investment decisions.
To stay up to date with the latest developments at Ananda, we encourage you to follow and join our social media channels which are:
· Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
Today 07:00
RNS Number : 0542C
Ananda Developments PLC
06 February 2024
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda Appoints Data and Analytics Expert
Ananda Developments Plc ('Ananda'), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions, is pleased to announce the appointment of Vitalii Ratushnyi as an adviser to the Company with a focus on data and analytics.
Vitalii is a data, analytics, and quantitative modelling expert. His appointment gives Ananda the analytical capability to better target its research activities by identifying potential current and new disease areas where cannabinoids may be efficacious. His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities. The Company's objective is to provide the evidence required to get cannabis-based medicines available on the NHS.
Ananda CEO Melissa Sturgess commented "We believe our ability to get to grips with large biological and genetic data sets will help us find opportunities for our cannabinoid medicines, guide the design of clinical trials and will be a cornerstone of our success. This work is critical for the rapid development of our clinical trials pipeline and intellectual property estate."
Biog...
Also sent same links/story to the Independent, who ran a piece in 2016 about a helium shortage. I'll stick with just those two because some of this would fall on deaf ears if I was to carpet spam say, the Mirror, Sun, etc, which are not really for serious investors. But the above picks may grab a few new eyes and ears.
Let's see what happens. GLA for another fun day.
I've e-mailed the Daily Mail Money section the story link this morning in the hope it'll encourage them to cover it. They do have a big readership including in Oz and the US now. Let's hope they can get it out there. Good for us, for HE1, for Tanz, and for newbies interested in making money/pension pot, etc. Everyone a winner.